Insmed Forecasts $263.9M Q4 Revenue with +7.01% EPS ESP
Insmed is set to report Q4 results on February 19 with consensus revenue of $263.9 million and an EPS loss estimate of $1.07, backed by a +7.01% EPS ESP. Its lead drug Arikayce maintains growth momentum, and newly approved Brinsupri is launching in the US and EU.
1. Q4 Earnings Preview
Insmed will report fourth-quarter results on February 19 with consensus revenue of $263.9 million and an expected EPS loss of $1.07 per share. The company’s +7.01% Earnings ESP indicates analysts raised their most recent estimates ahead of the release.
2. Historical Earnings Performance
Insmed has missed consensus EPS forecasts in each of the last four quarters, delivering an average negative surprise of 20.64%. This track record sets a low bar ahead of the upcoming report.
3. Product Developments and Rollout
Arikayce continues to gain traction in targeted patient populations, driving recurring sales growth. Brinsupri, approved for non-cystic fibrosis bronchiectasis, is rolling out commercially in both the US and EU, representing a new revenue stream.